



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : A61K 39/00, 39/38, 38/28, C07K 1/00, 14/00, 17/00	A1	(11) International Publication Number: WO 96/39176 (43) International Publication Date: 12 December 1996 (12.12.96)
(21) International Application Number: PCT/US96/10386 (22) International Filing Date: 5 June 1996 (05.06.96)  (30) Priority Data: 465,592 5 June 1995 (05.06.95) US  (71) Applicants: BRIGHAM & WOMEN'S HOSPITAL [US/US]; 75 Francis Street, Boston, MA 02115 (US). YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM [IL/IL]; 46 Jabotinsky Street, 91042 Jerusalem (IL).  (72) Inventors: CHEN, Youhai; 205 Cherry Hill Lane, Broomall, PA 19008 (US). WEINER, Howard, L.; 114 Somerset Road, Brookline, MA 02146 (US). FRIEDMAN, Aharon; Apartment 3, 7 Shkolnek, 76100 Rehovot (IL).  (74) Agents: GOGORIS, Adda, C. et al.; Darby & Darby P.C., 805 Third Avenue, New York, NY 10022 (US).		(81) Designated States: AU, BR, CA, HU, IL, JP, KR, NO, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  Published With international search report.

63

(54) Title: USE OF ORAL TOLERANCE TO SUPPRESS BOTH Th1 AND Th2 IMMUNE RESPONSES AND TO SUPPRESS ANTIBODY PRODUCTION

## (57) Abstract

This invention relates to methods for orally administering autoantigens to suppress specific Th2 as well as Th1 immune responses and antibody production. The invention finds applicability in the treatment of antibody-mediated autoimmune diseases.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

5

10

USE OF ORAL TOLERANCE TO SUPPRESS  
BOTH Th1 AND Th2 IMMUNE RESPONSES  
AND TO SUPPRESS ANTIBODY PRODUCTION

Field of the Invention

15

This invention relates to methods for suppression of specific Th2 (as well as Th1) immune responses and antibody production and finds applicability in the treatment of antibody-mediated autoimmune diseases.

20

Background of the Invention

The use of the oral route to tolerize the immune system against antigens (foreign or self) has been employed to suppress immune response associated with T-cell mediated human autoimmune diseases (1,2). Antigen feeding as a means to generate peripheral tolerance in CD4+ cells has been thus far successful in tolerization of Th1 type responses, while those of Th2 lymphocytes appear to be intact (3-5). Maintenance of Th2 responses has value in regulating Th1 responses during the induction of oral tolerance to Th1-mediated immune diseases (bystander suppression). In antibody-mediated autoimmunity, however, Th2 responses play an important pathogenetic role. It would be therefore desirable to suppress Th2 autoimmune responses associated with antibody-mediated autoimmune diseases. However, up to the present time, Th2 suppression has not been induced as the result of orally-induced tolerance.

35

There have been several reports (4, 19, 34, 35) that oral administration of single doses and relatively high amounts of antigen in experimental models of Th1-mediated autoimmune disease has induced T-cell anergy, especially anergy of Th1 responses. Anergy is a state of antigen-specific T-cell

40

nonresponsiveness. However, the degree to which anergy contributes to Th2 tolerance is still under investigation.

Difficulties in generating tolerance of Th2 lymphocytes *in vitro* (6-8) or of Th2-mediated antibody production *in vivo* have been encountered in other experimental systems in which tolerance was induced by intravenous (I.V.) or intraperitoneal (I.P.) administration of soluble antigens (9-12). Thus, after tolerization by the oral or parenteral route, IL-2 and IFN $\gamma$  were not produced in cultures, and a diminished IgG2a antibody response was observed *in vivo* (tolerance of Th1 responses). In contrast, IL-4 production *in vitro* and IgG1 responses *in vivo* were intact (intact Th2 responses) (3-11). It appeared, therefore, that Th2 lymphocytes were resistant to tolerance induction, whether by oral or parenteral route.

B-cells have been even more resistant to suppression by tolerization techniques.

On the other hand, the oral route of exposure to antigen has evolved as an efficient pathway to generate peripheral tolerance to food antigens (13). As a result, both cell-mediated immunity (controlled by Th1 lymphocytes) and hypersensitivity (controlled by Th2 lymphocytes) to food antigens appear to be prevented in normal subjects.

In light of this, the present inventors endeavored to discover oral tolerance techniques that would cause suppression of specific Th2 lymphocytes. Since Th2 lymphocytes play an important role in antibody production, successful suppression of Th2 responses would prove a useful tool in suppressing abnormal antibody-mediated immune responses.

Oral tolerance is a clinically attractive method to treat immune dysfunctions (such as autoimmune diseases) for several reasons:

(1) Absence of toxicity - No toxicity has been observed in clinical trials involving oral administration of bovine myelin (which contains MBP and PLP) to humans afflicted with multiple sclerosis; or oral administration of chicken Type II collagen to humans afflicted with rheumatoid arthritis; or oral administration of bovine S-antigen to humans afflicted

with uveoretinitis; or oral administration of insulin to healthy volunteers.

(2) Avoidance of global immunosuppression - Previously available treatments involved the administration of steroids, or cyclosporine A, or chemotherapeutic drugs or biologic response modifiers and other global immunosuppressive agents which diminished the ability of the treated subject to defend against pathogens (and was accompanied by various other known side effects ranging from unpleasant to life-threatening). Oral tolerance on the other hand would accomplish specific suppression of abnormal immune responses.

(3) Convenience of therapy.

Oral tolerance to autoantigens (defined solely for purposes of this background discussion as antigens that are primary targets of attack by the immunoregulatory system) and bystander antigens (briefly, antigens specific to the organ or tissue affected in a T-cell mediated autoimmune disease but not necessarily a target of autoimmune attack) has been induced successfully by daily (and/or less frequent) administration of such antigens and has been employed to suppress Th1-mediated autoimmune reactions or responses, and thus to suppress (T-cell mediated) autoimmune disease in both animals and humans: Thompson, H.S.G. et al. *Clin. Exp. Immunol.*, 64:581-586, 1986; Nagler-Anderson, C. et al. *Proc. Nat'l. Acad. Sci. (USA)* 83: 7443-7446, 1986; Higgins, P. et al. *J. Immunol.* 140: 440-445, 1988; Zhang, J.A. et al. *Proc. Natl. Acad. Sci. (USA)* 88:10252-10256, 1991; Nussenblatt, R.B. et al., *J. Immunol.*, 144:1689-1695, 1990; Weiner, H.L. et al. *Science*, 259:1321-1324, 1993; Trentham, D.E. et al., *Science*, 261, 1727-1730, 1993. In the case of Th1-mediated autoimmune disease, oral tolerance results in active suppression, i.e., elicitation of antigen specific T-cells which are or include Th2 cells and which are targeted to the afflicted tissue and exert local suppressive effect.

Methods and compositions useful in suppression of an immune response associated with a T-cell mediated or T-cell dependent autoimmune disease by orally induced tolerance (or by tolerance induced by inhalation) using daily or less

frequent administration of autoantigens or more generally bystander antigens with and without enhancers have been described in various patents and patent applications by the present inventors and their co-workers: Ser. No. 07/843,752, 5 filed February 28, 1992; Ser. No. 08/202,677, filed February 25, 1994; Ser. No. 08/419,502, filed April 10, 1995; Ser. No. 08/419,505, filed April 10, 1995; Ser. No. 08/235,121, filed April 28, 1994; Pat. No. 5,399,347, issued March 21, 1995; Ser. No. 08/297,395, filed August 11, 1994; Ser. No. 08/046,354, 10 filed April 9, 1993; Ser. No. 08/420,979, filed April 10, 1995; Ser. No. 08/420,980, filed April 10, 1995; Ser. No. 08/105,912, filed August 10, 1993; Ser. No. 08/279,275, filed July 22, 1994; Ser. No. 08/328,562, filed October 24, 1994. These techniques induce suppression of Th1 responses, which is 15 beneficial in the treatment of T-cell mediated or T-cell dependent autoimmune diseases. The Th2 responses are not suppressed and are relied upon to regulate Th1 responses (bystander suppression).

It would nevertheless be desirable to devise methods 20 to extend the use of orally-induced tolerance to the treatment of other immune dysfunctions. One such class of immune dysfunctions are antibody-mediated autoimmune diseases, (for example certain aspects of systemic lupus erythematosus, autoimmune thyroiditis, myasthenia gravis, glomerulonephritis, 25 autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, pemphigus vulgaris, Grave's disease, insulin resistance (encountered in Type II diabetes), and pernicious anemia).

### 30 Objects of the Invention

It is an object of this invention to devise methods and compositions for suppressing Th2 autoimmune responses (alone or together with Th1 responses) via the oral route.

Another object is to devise methods and compositions 35 for suppressing abnormal antibody-mediated immune responses.

A further object is to devise methods and compositions for treating antibody-mediated autoimmune

responses, in order to treat antibody-mediated autoimmune diseases.

#### Summary of the Invention

5 In one aspect the present invention relates to a method for treating a mammal suffering from an antibody-mediated autoimmune disease comprising orally administering to said mammal at least one autoantigen (as defined below) specific for said disease; and continuing said administration  
10 for a period of time until a Th2 cell mediated autoimmune response associated with said disease is suppressed. The amount of said antigen, the schedule (frequency) of said administration, and the period of time are selected to effect said suppression.

15 In another aspect, the present invention relates to a method for treating a mammal suffering from an antibody-mediated autoimmune disease comprising administering to said mammal via the oral route an autoantigen specific for said disease for a period of time sufficient to accomplish at least  
20 one of the following: reduce the number of autoreactive Th2 cells in said mammal recognizing said autoantigen; reduce the number of autoreactive antibodies in said mammal recognizing said autoantigen; and eliminate or decrease the severity of at least one clinical symptom or indicator associated with said  
25 disease.

In a further aspect, the present invention relates to a method for treating a mammal suffering from an antibody-mediated autoimmune disease comprising parenterally administering to said mammal at least one autoantigen specific  
30 for said disease; and continuing said administration until a Th2 cell mediated autoimmune response associated with said disease is suppressed.

Other aspects of the invention relate to suppression of a Th2 (or both Th2 and Th1) response associated with  
35 antibody-mediated autoimmune disease by oral administration of at least one autoantigen specific for the antibody-mediated autoimmune disease in an amount, a frequency of administration and for a period of time effective to suppress said response.

Further aspects of the invention will be apparent to those skilled in the art in light of the present description, and accompanying claims and drawings in which:

5 BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A and 1B are plots of spleen cell proliferation averages  $\pm$  SEM in absorbance units at 570-630nm against stimulating antigen concentration *in vitro*. Mice were continuously exposed to OVA in drinking water for 20 days and  
10 primed by OVA-CFA (open triangles). Control mice were primed by OVA-CFA (filled circles) or CFA alone (open circles). Pooled erythrocyte depleted spleen cells were prepared 10 days after immunization and stimulated by different concentrations of OVA (Fig. 1A) or PPD (Fig. 1B).

15 Figures 2A, 2B, 2C and 2D are plots of antibody titers (averages  $\pm$  SEM) from individual mice (for all isotypes) expressed in absorbance units at 405 nm against reciprocal serum dilution. Mice were continuously fed with OVA (open triangles). Control mice were primed by OVA-CFA (filled  
20 circles) or by CFA alone (open circles). Serum samples were collected 15 days after immunization and individually assayed for IgG2a (Fig. 2A), IgG2b (Fig. 2B), IgG1 (Fig. 2C) and IgE (Fig. 2D).

Figure 3 is a plot of OVA specific cytokine release  
25 or antibody titers v. amount of fed antigen. Mice were continuously fed with different dosages of OVA for 20 days and primed by OVA-CFA. Cytokine (circles) and antibody (triangles) secretion respectively are shown for IL-2 (solid circles) and IL-4 (open circles). Cytokine results are averages  $\pm$  SEM of  
30 quadruplicate cultures and are expressed in absorbance units at 570-630nm. IgG2a (solid triangles) and IgG1 (open triangles) are also shown. Antibody titers are averages  $\pm$  SEM of titers from individual mice and are expressed in absorbance units at 405nm.

35 Figure 4 is a plot of average antibody binding  $\pm$  SEM from individual mice at a serum dilution of 1:400, presented in absorbance units at 405 nm against time of exposure to anti-



gen. IgG1 are shown by open circles and IgG2a are shown by solid circles.

Figure 5A is a plot of the percentage of V $\beta$ 8.2+ T-cells which are also CD4+ versus antigen (OVA) feedings over feeding frequency. Mice were fed 0.5 (open circles), 5 (filled squares) or 500 mg (filled circles) of OVA every other day for five feedings, and T-cells were harvested for analysis prior to, and 24 hours after, each feeding.

Figures 5B and 5C are fluorescence contour plots showing the probability of incidence of T-cells of various subtypes; CD4+ cells are depicted in the upper right-hand quadrant.

Figure 6A is a plot of the percentage of V $\beta$ 8.2+ cells which are undergoing apoptosis versus antigen (OVA) feedings over feeding frequency. V $\beta$ 8.2+ cells from mice fed 0.5 (filled circles), 5 (filled squares), and 500 mg (closed circles) were analyzed for the presence of degraded DNA which indicates apoptosis by staining with acridine orange.

Figures 6B and 6C are Forward Angle Light Scatter (FALS) plots showing the incidence of acridine orange staining (indicating dying cells) for various T-cell subtypes.

Figure 7A is a plot of percentage of V $\beta$ 8.2+ cells which are actively dividing versus antigen (OVA) feeding frequency. V $\beta$ 8.2+ cells from mice fed 0.5 (open circles), 5 (filled squares), and 500 mg (filled circles) were analyzed for DNA content which indicates active division, by staining with propidium iodide.

Figures 7B and 7C are FALS plots showing the incidence of DNA content for various T-cell subtypes from control(B) and OVA-fed animals.

Figure 8A-8E are plots showing the concentrations of cytokines IL-2 (8A), IL-4 (8B), IL-10 (8C), (all in pg/ml) and IFN- $\gamma$  (8D) and TGF- $\beta$  (8E) (both in ng/ml) versus antigen (OVA) feeding frequency.

#### Detailed Description of the Invention

The following terms, when used in this disclosure, shall have the meanings ascribed to them below:

"Mammal" is defined herein as any warm-blooded higher vertebrate organism (including a human) having an immune system and being susceptible to an autoimmune disease.

"Autoimmune disease" is defined herein as a  
5 spontaneous or induced malfunction of the immune system of mammals, including humans, in which the immune system fails to distinguish between foreign immunogenic substances within the mammal and/or autologous substances and, as a result, treats autologous tissues and substances as if they were foreign and  
10 mounts an immune response against them. The term includes human autoimmune diseases and animal models therefor.

"Autoantigen" is any substance or a portion thereof normally found within a mammal that invokes an immune response within an individual, i.e. that is recognized by activated T-  
15 cells of the mammal or by antibodies in the mammal. In an autoimmune disease, such an antigen may be or may become the primary (or a primary) target of attack by the immunoregulatory system. The term also includes antigenic substances that induce conditions having the characteristics of an autoimmune  
20 disease when administered to mammals. Additionally, the term includes peptidic subclasses consisting essentially of immunodominant epitopes or immunodominant epitope regions of autoantigens. Immunodominant epitopes or regions in induced autoimmune conditions are fragments or portions of an  
25 autoantigen that can be used instead of the entire autoantigen to induce the disease. In humans afflicted with an autoimmune disease, immunodominant epitopes or regions are fragments or portions of antigens specific to the tissue or organ under autoimmune attack and recognized by a substantial percentage  
30 of autoimmune attack T-cells or antibodies from a patient or a group of patients. See, e.g., 08/426,784 for determination of T-cell immunodominant epitopes. Autoantigens and their immunodominant epitopes that elicit antibodies can be identified by antibody binding tests, ELISA assays or dot blot  
35 analysis using whole antigens or peptide fragments of a particular autoantigen (overlapping peptide method).

"Treatment" of an autoimmune disease is intended to include both treatment to prevent or delay the onset of an

autoimmune disease (or to prevent or delay the manifestation of clinical or subclinical, e.g., histological, symptoms thereof), as well as therapeutic suppression or alleviation of symptoms after the manifestation of such autoimmune disease.

- 5 In either case, treatment is accomplished by abating autoimmune attack and preventing or slowing down autoimmune tissue destruction. "Abatement", "suppression" or "reduction" of autoimmune attack or reaction encompasses partial reduction or amelioration of one or more symptoms of the attack or reaction,
- 10 i.e. reduction in number of activated autoreactive T-cells or in number of autoreactive antibodies. A "substantially" increased suppressive effect (or abatement or reduction) of autoimmune reaction means a significant decrease in one or more markers or histological or clinical indicators of autoimmune
- 15 reaction or disease. Nonlimiting examples of symptoms associated with various autoimmune diseases are given below. In each case an improvement in one or more symptoms reported by the patient (e.g. fatigue) or observed by the attending physician or determined by quantitative or semiquantitative
- 20 techniques can be used to assess efficacy of treatment according to the invention.

DISEASE	SYMPTOMS/DIAGNOSTIC MARKERS
25 Autoimmune hemolytic anemia	<ul style="list-style-type: none"> <li>- anemia</li> <li>- splenomegaly</li> <li>- spherocytosis of blood smears</li> <li>- polychromatophilia with high MCHC</li> <li>- "warm reading" positive direct antiglobulin test (DAG)</li> </ul>
30 Infertility due to Sperm Antigen Auto-antibodies	<ul style="list-style-type: none"> <li>- autoantibodies to sperm detected by agglutination and sperm immobilization (gelatin, tube-slide, slide, tray, or capillary tube agglutination test)</li> <li>- passive hemagglutination assay (Mathur et al., <u>J. Immunol. Methods</u> 1979, 30:381-393)</li> <li>- radiolabel antiglobulin test (Haas, et al <u>NEJM</u>, 1980, 303:722-727)</li> </ul>
Sjögren's Syndrome (SS)	<ul style="list-style-type: none"> <li>- autoantibodies to SS in serum and saliva</li> <li>- rheumatoid factors</li> <li>- inflammation of salivary glands and lachrymal glands</li> </ul>

DISEASE	SYMPTOMS/DIAGNOSTIC MARKERS
Systemic lupus erythematosus	<ul style="list-style-type: none"> <li>- anemia</li> <li>- fatigue</li> <li>- malar rash</li> <li>- discoid rash</li> <li>- oral ulcers</li> <li>- arthritis</li> <li>- serositis</li> <li>- neurological disorder measured by abnormal electroencephalogram or elevated protein levels in cerebrospinal fluid</li> <li>- autoantibodies to antinuclear antigens determined by immunoassay taken in the absence of drugs known to induce antinuclear antigens.</li> <li>- renal disorder measured by deposit of immunoglobulins, proteinuria, or cellular casts.</li> </ul>
5 Myasthenia gravis	<ul style="list-style-type: none"> <li>- autoantibodies to acetylcholine receptor determined by immunoassay (preferred marker)</li> <li>- ocular muscle weakness</li> <li>- fatigue</li> <li>- anticholinesterase response</li> <li>- electrophysiological tests to measure response to nerve stimulation</li> <li>- muscle strength (preferred marker)</li> </ul>
Autoimmune thrombocytopenic purpura	<ul style="list-style-type: none"> <li>- antibodies to platelets</li> </ul>
10 Primary Biliary cirrhosis	<ul style="list-style-type: none"> <li>- serum alkaline phosphatase increase</li> <li>- bilirubin increase</li> <li>- IgM and IgG increase</li> <li>- hyperlipidemia</li> <li>- lipoprotein X</li> <li>- serum bile salts increased</li> </ul>
Ulcerative colitis	<ul style="list-style-type: none"> <li>- improvement assessed by reduction in fever, decreased bloody diarrhea and improvement in appetite</li> </ul>
15 Wegener's Granulomatosis	<ul style="list-style-type: none"> <li>- anemia</li> <li>- sedimentation rate</li> <li>- rheumatoid factor</li> <li>- uremia</li> </ul>
Insulin resistance	<ul style="list-style-type: none"> <li>- measurement of anti-insulin antibodies</li> <li>- ketoacidosis</li> <li>- hyperglycemia</li> <li>- hyperinsulinemia</li> </ul>

DISEASE	SYMPTOMS/DIAGNOSTIC MARKERS
Graves disease	<ul style="list-style-type: none"> <li>- measurement of RAIU, serum T<sub>4</sub> and T<sub>3</sub>, RT<sub>3</sub>U and FT<sub>4</sub>I</li> <li>- thyroid enlargement</li> <li>- weakness, weight loss, nervous instability, tremor, intolerance to heat, hyperhidrosis, palpitation and hyperdefecation (thyroid function and heart rate are preferably used to monitor therapy)</li> </ul>
Pemphigus Vulgaris	<ul style="list-style-type: none"> <li>- oral or mucosal lesions (light microscopy examination of epidermis immunofluorescent detection of autoantibodies are preferred to monitor therapy)</li> </ul>
5 Glomerulonephritis	<ul style="list-style-type: none"> <li>- hematuria</li> <li>- red cell cast excretion</li> <li>- proteinuria</li> <li>- fluid retention</li> </ul>
scleroderma	<ul style="list-style-type: none"> <li>- observation of afflicted tissue</li> <li>- esophageal dysfunction</li> <li>- rheumatoid factor</li> <li>- antinuclear and serum antinuclear antibodies</li> <li>- anticentromere antibodies</li> <li>- antibodies against specific scleroderma antigens</li> </ul>
myositis	<ul style="list-style-type: none"> <li>- observation of afflicted tissue</li> <li>- arthralgia</li> <li>- muscle weakness</li> <li>- muscle enzymes (creatin kinase, transaminase)</li> </ul>
vasculitis	<ul style="list-style-type: none"> <li>- observation of afflicted tissue (vascular and skin lesions)</li> </ul>

10

Alternatively, patient improvement can be assessed by assay to determine whether there has been a significant reduction in the frequency of autoreactive T-cells; or in the frequency of autoreactive antibodies, or both.

15

"Oral" administration includes oral, enteral or intragastric administration, and more generally any administration of an active ingredient that brings the ingredient in contact with the immune system at the gut-associated lymphoid tissue.

20

"Parenteral" administration includes subcutaneous, intradermal, intramuscular, intravenous, intraperitoneal or intrathecal administration. Intravenous administration is preferred. Parenteral administration must be free of co-

stimulatory substances which might cause an undesirable immune reaction.

### Rationale

5           The present inventors conceived that it should be possible to suppress both Th1 and Th2 abnormal immune responses (whether these responses were directed against an external antigen or a self-antigen) via orally or parenterally induced tolerance.

10           The present inventors observed that maintenance of exposure to antigen appeared to be important for the persistence of tolerance in various different contexts: orally induced tolerance to OVA antigen in mice immunized with OVA (14); parenterally induced tolerance due to induction of clonal  
15 anergy (15); and anergic cells removed from contact with the antigen by transplantation in a mouse strain lacking the antigen (16). The inventors decided to test their hypothesis in the context of orally induced tolerance by extending the exposure of the immune system (by contact with the gut-  
20 associated lymphoid tissue) to orally administered antigen and attempting to define conditions for induction of tolerance against Th2 lymphocytes.

          The simplest system for testing this was to make defined quantities of antigen available to the experimental  
25 animals throughout their daily activity period while being able to assess antigen consumption as well as its frequency. It was therefore decided to add the antigen used for immunization to the animals' drinking water.

          Another consideration was to devise a system for  
30 testing the principle of this invention in a manner that would be of as general applicability as possible, in light of the present skill and knowledge in the art. It was decided to use OVA as the tolerizing agent (fed antigen) and as the immunogen. In Friedman, A. et al. 1994, PNAS (USA) 91:6688, it was  
35 demonstrated that Th1 and Th2 responses in the autoimmune disease model EAE (a model for multiple sclerosis) were similar to those seen in induction of immunity by OVA. Furthermore, oral tolerization had been effective in suppressing an immune

response to OVA (Richman, L.K., et al. J. Immunol. 121:2429, 1978). The applicability of this oral tolerization treatment (i.e. the treatment involving prolonged exposure to antigen through "multi-dose administration" as defined below) to various disease states characterized by one or more undesirable immune responses would depend on the ability of this regime to suppress various immune responses. The T-cells of the subject react to an antigen they recognize regardless of whether that antigen is endogenous (as in autoimmunity) or not (as in the present experimental models).

The present inventors found that multi-dose daily oral administration of antigen to a subject to be treated (i.e. a subject that mounts an immune response to that antigen) achieves the suppression of not only Th2 but also Th1 immune responses to the same antigen. "Multi-dose administration" or "multi-dose exposure" or "exposure to multiple doses" encompasses administration occurring at a plurality of spaced apart intervals during the same day as further described below, as well as continuous administration either by intragastric or parenteral infusion, or by ingestion of a sustained-release dosage form. The term thus refers to a schedule or frequency of administration.

The thus induced tolerance of not only Th2 by also Th1 lymphocyte responses entrained (and was confirmed by) profoundly suppressed numbers of *in vivo* secreted antigen-specific antibodies, including IgG1 and IgE (which are controlled by Th2 cytokines, with IgE being considered to be exclusively Th2-controlled) as well as IgG2a and IgG2b (which are controlled by IFN- $\gamma$ , a Th1 cytokine).

Tolerance of both Th1 and Th2 responses to the multi-dose fed antigen was confirmed by: (i) failure of T-cells from animals fed antigen by multi-dose administration to proliferate *in vitro* to the fed antigen (which also had been used for immunization), as well as by (ii) suppression of Th1 and Th2 cytokine secretion and cytokine gene expression by the tolerized T-cells. In fact, suppression of cytokines was demonstrated by ELISA, CT.4S cell proliferation and RT-PCR

(reverse transcriptase polymerase chain reaction). These tests demonstrate tolerization of Th2 lymphocytes.

The present inventors were the first to achieve complete tolerization of Th2 lymphocytes as demonstrated both  
5 in vitro and in vivo.

Using another approach, the present inventors determined further that even larger amounts of antigen orally administered also bring about suppression of Th2 (and Th1) responses even when not administered in multiple daily doses.  
10 Specifically, in experiments involving transgenic mice expressing essentially only a T-cell receptor specific to OVA (V $\alpha$ 13/V $\beta$ 8.2TcR), considerable suppression of both Th2 and Th1 responses was achieved by feeding large amounts of antigen intermittently in single doses. The mechanism of suppression  
15 is substantially through deletion of antigen-specific Th2 and Th1 cells. The inventors concluded that this approach can be used to induce tolerance in Th2-mediated (antibody-mediated) responses associated with autoimmune disease. This "high-dose" oral tolerization (in which antigen can be administered only  
20 once daily or according to a less frequent administration schedule, as described below) can be used as an alternative or an adjunct to multi-dose oral tolerization. In fact, in a preferred embodiment, subjects to be treated will be administered both high doses of antigens and multiple daily  
25 doses.

In Examples 6-9, the animal model used involved animals that have only T-cells that are reactive with the same antigen as that used for immunization (OVA). The rationale for applicability of these findings to human antibody-mediated  
30 autoimmune disease is the same as that described above for the multi-dose experiments.

Amounts and Schedule (Frequency and Duration)  
for Oral Administration

35 Multi-dose daily autoantigen administration (and attendant delivery of relatively high amounts of antigen to a locus exposed to the treated subject's immune system) achieves suppression of Th2 as well as Th1 responses. (Suppression of



only Th1 requires only relatively modest amounts of antigen and intermittent administration: for example, in humans, rheumatoid arthritis symptoms have been suppressed with as little as 0.1 mg of collagen II administered once a day, for  
5 one month, followed by administration of 0.5 mg collagen II administered daily for two months.)

Relatively protracted exposure to antigen enhances tolerization of Th2 responses. For example, mice need to be fed with a multi-dose daily regimen requiring relatively large  
10 amounts of antigen (see infra) for more than 15 and preferably at least 20 days.

However, suppression of Th2 responses can also be achieved in mice by single dose intermittent (e.g., once daily, every other day or twice a week) administration of even higher  
15 doses of antigen. Again, continuing the administration over a period of time increases suppression.

Thus, the amount of antigen effective to suppress Th2 responses to that antigen depends partially on the schedule (frequency) of its administration. Suppression, even complete  
20 suppression of Th2 responses to a particular antigen (OVA) can be achieved by administering e.g. 4 mg of antigen in several divided daily doses to mice whereas the same amount (4 mg) of OVA, if administered once a day, achieved only a slight suppression of IL-2 (see, e.g. Table III).

25 A substantially higher amount of an antigen is needed to suppress Th2 responses if the antigen is administered once daily or intermittently. Suppression of Th2 responses is typically achieved after a number of feedings, in mice, typically three or more. Thus after three feedings of 5 or 50  
30 mg of antigen on alternate days partial OVA-specific Th2 suppression (predominately T-cell deletion) was achieved in mice. Substantially more profound suppression resulted from feeding 500 mg of OVA according to the same schedule.

Accordingly, to induce suppression of both Th1 and  
35 Th2 responses in mice oral administration of daily amounts within the general range of 2 mg - 500 mg depending on the antigen would be useful, preferably, 5 mg to 100 mg. The schedule of administration should be at least 3 and preferably

at least 5 times a day, for smaller amounts within this range but may be less frequent e.g. once daily, once every other day, or twice a week as the amount of antigen per treatment is increased.

- 5 In humans, to suppress Th2 responses associated with antibody-mediated autoimmune disease using multi-dose oral administration, an autoantigen should be administered orally at least three and preferably at least five or six times a day at spaced apart intervals (e.g. with and/or between meals).
- 10 For humans, the total daily dosage of multi-dose administration will be within the general range of 2.5 - 1,000 mgs of autoantigen depending on the autoantigen, preferably within the range of 15 - 500 mgs divided among several dosages (as stated above). No maximum effective number of dosages or total daily
- 15 intake of antigen has been discerned. Twelve daily doses provide a practical limit.

- When high-dose intermittent administration is used in humans, antigen could be administered less often: twice daily, once daily, three-times weekly, twice weekly or once a
- 20 week. In that event, the amount of administered antigen should be within the range of 30 mg - 10 g per treatment depending on the antigen.

- In either case, the duration of treatment in humans should be a minimum of two weeks, and typically three months,
- 25 and may be continued indefinitely or as long as benefits persist. The treatment may be discontinued if desired (in the judgment of the attending physician) and the patient monitored for signs of relapse. If clinical symptoms or other disease indicators show that the patient is relapsing, treatment may
- 30 resume.

- As will be understood by those skilled in the art, the dosage will vary with the disease, the antigen administered and may vary with the sex, age, and physical condition of the patient as well as with other concurrent treatments being
- 35 administered. Consequently, adjustment and refinement of one or both of the dosages used and the administration schedules will preferably be determined based on these factors and especially on the patient's response to the treatment. Such

determinations, however, require no more than routine experimentation, as illustrated in Examples A-C below.

#### Antigens that May be Used to Induce Tolerance

5           Suitable antigens include autoantigens (as defined in the present detailed description) specific for a particular antibody-mediated autoimmune disease.

Nonlimiting examples of autoantigens for each of various antibody-mediated autoimmune diseases are:

Disease	Antigen for Multi-dose Administration to Humans
Autoimmune Thyroiditis	thyrotropin receptor thyroglobulin thyroid stimulating hormone receptor (TSHR)
15   Systemic Lupus Erythematosus	nuclear antigens recognized by anti-nuclear antibodies, e.g., SS-A antigen; La antigen (also known as SS-P); DNA (both double stranded and single stranded); RNA; Sm-(Smith) antigen; nRNP (nuclear ribonucleoprotein) antigen; and fragments thereof such as the 60 kd and 52 kd proteins of SSA; b', d' and d proteins of Sm antigen; RNP 70 kd antigen; and RNPc of NRNP. These antigens have been described in Wagatsuma et al. <u>Mol. Immunol.</u> 30: 1491-1498, 1993; Priujn, in <u>Manual of Biological Markers of Disease (BP4.2: 1-14)</u> Kluwer Academic Publishers, Dordrecht/Boston/London 1994; and Smeenk, (p. B2.1: 1-14); Ku antigen, see infra.
Myasthenia Gravis	acetylcholine receptor, Waser, et al., <u>Eur. J. Pharm.</u> 172: 231-238, 1989
20   Insulin Resistance	insulin receptor (e.g. U.S. Pat. No. 5,385,888)
Autoimmune Hemolytic Anemia	red blood cells and antigens associated with them, e.g. Rh antigens disclosed in Agre, P. et al. <u>Blood</u> , 78:551-563, 1991
25   Autoimmune Thrombocytopenic Purpura	platelets; platelet membrane antigens, e.g. glycoprotein IIb-IIIa, Kiefel, V. et al. <u>Seminars in Hematology</u> 29:26-33, 1992
Glomerulonephritis	glomerular basement membrane and antigens associated with it
30   Ulcerative Colitis	autoantigen (40kd) associated with disease, Das et al., <u>J. Immunol.</u> 139: 77-84, 1987; autoantigen target of perinuclear antineutrophil cytoplasm antibodies

Disease	Antigen for Multi-dose Administration to Humans
Pemphigus Vulgaris	desmoglein, keratins, Type XVII collagen, Type IV collagen
5 Primary Biliary Cirrhosis	Ku antigen (Factor E1BF) (EBP-80), Mimori et al., <u>J. Clin. Invest.</u> 68: 611-620 (1981); dihydrolipoamide acetyltransferase and dihydrolipoamide dehydrogenase
Myositis	aminoacyl-tRNA synthetases such as Jo-1 antigen PL-7, PL-12, EJ and OJ antigens; PM/ScI complex; PM/ScI-100; PM/ScI-75
Wegener's Granulomatosis	proteinase-3, Kao et al., <u>J. Clin. Invest.</u> 82: 1963-1973, 1988; antineutrophil cytoplasmic autoantibodies (ANCA)
10 Grave's disease	TSHR
Vasculitis	ANCA-antigens; serine protease proteinase-3
Scleroderma	DNA topoisomerase I (110KD); scleroderma 70 antigen (70KD); scleroderma 86 antigen (86KD); scleroderma 110 antigen; centromere proteins (CENP-A, CENP-B, CENP-C) <u>Manual of Biol. Markers of Disease</u> B.5. 2:1-17, 1994; PM/ScI antigen; PM/ScI-100; PM/ScI-75

15 All of the foregoing are well-known and extensively characterized in the literature. The nucleotide and amino acid sequences of several of the foregoing antigens have been elucidated and some are commercially available. Where individual antigens are not known, impure preparations  
 20 containing lysates from afflicted tissue (from the same or a related species) can be used prepared by well-known techniques.

Additional autoantigens can be identified by screening antigens for binding with antibodies or activated T-cells from the patient.

25

#### Formulations

Administration of more than one autoantigen is possible, and in fact desirable when the patient's T-cells or autoreactive antibodies recognize more than one antigen. In  
 30 cases where the autoantigen is unknown, entire tissue extracts

(i.e., tissue lysates) from the same or a related species can be administered.

Suitable formulations for use in tolerization of Th2-responses according to the present invention can be in any suitable orally administrable form. For example, a pill, a liquid, a capsule containing an effective amount of antigen. Each oral formulation may additionally comprise inert constituents including pharmaceutically acceptable carriers, diluents, fillers, solubilizing or emulsifying agents and salts as is well-known in the art. For example, tablets may be formulated in accordance with conventional procedures implying solid carriers well-known in the art. Capsules may be made from any pharmaceutically acceptable materials, such as gelatine or cellulose derivatives. Nonlimiting examples of solid carriers include starch, sugar, bentonite, silica and other commonly used inert ingredients. Diluents can include *inter alia* saline, syrup, dextrose and water.

The autoantigens used in the present invention can also be made up in liquid formulations or dosage forms such as, for example, suspensions or solutions in a physiologically acceptable aqueous liquid medium. Such liquid media include water, or suitable beverages, such as fruit juice or tea which will be convenient for the patient to sip at spaced apart intervals throughout the day. When given orally in liquid formulations the antigen may be dissolved or suspended in a physiologically acceptable liquid medium, and for this purpose the antigen may be solubilized by manipulation of its molecule (e.g., hydrolysis, partial hydrolysis or trypsinization) or adjustment of the pH within physiologically acceptable limits (e.g. 3.5 to 8). Alternatively, the antigen may be reduced to micronized form and suspended in a physiologically acceptable liquid medium. For parenteral administration the antigen should be administered in a solution.

Sustained released oral delivery systems are also contemplated and are preferred. Nonlimiting examples of sustained release oral dosage forms include those described in U.S. Patent No. 4,704,295 issued November 3, 1987; No. 4,556,552 issued December 3, 1985; No. 4,309,404 issued January

5, 1982; No. 4,309,406 issued January 5, 1982; No. 5,405,619 issued April 10, 1995; WO 85/02092 published May 23, 1985; No. 5,416,071 issued May 16, 1995; No. 5,371,109 issued December 6, 1994; No. 5,356,635 issued Oct. 18, 1994; No. 5,236,704 issued August 17, 1993; No. 5,151,272 issued September 29, 1992; No. 4,985,253 issued January 15, 1991; No. 4,895,724 issued January 23, 1990; No. 4,675,189 issued June 23, 1987.

Sustained release oral dosage forms coated with bioadhesives are preferred. Examples are compositions disclosed in EP 516,141; No. 4,226,848, Nagai et al., Oct. 1980; No. 4,713,243, Schiraldi et al., Dec. 1987; No. 4,940,587, Jenkins et al., July 1990; WO 85/02092; EPO 0 205 282; Smart, et al., J. Pharm. Pharmacol. 36:295-99, 1984; Sala et al., Proceed. Intern. Symp. Control. Rel. Bioact. Mater. 16:420-21, 1989; Hunter et al., International Journal of Pharmaceutics 17:59-64, 1983; Bioadhesion - Possibilities and Future Trends, Kellaway, Course No. 470, May 22-24, 1989.

Preferred commercially available sustained release formulations and devices (the latter can be used in infusion described below) include those marketed by ALZA Corporation, Palo Alto, CA, under tradenames ALZET, INFUSET, IVOS, OROS, OSMET, or described in one or more U.S. patents: No. 5,284,660 issued Feb. 9, 1994; No. 5,141,750 issued Aug. 25, 1992; No. 5,110,597 issued May 5, 1992; No. 4,917,895 issued April 17, 1990; No. 4,837,027 issued June 6, 1989; No. 3,993,073 issued Nov. 23, 1976; No. 3,948,262 issued April 6, 1976; No. 3,944,064 issued March 16, 1976; No. 3,699,963; PCT/US93/10077; PCT/US93/11660; EP 259013; and EP 354742.

Sustained release compositions and devices are particularly adapted for use in the present invention because they serve to prolong contact between the antigen and the gut-associated lymphoid tissue (GALT) and thus prolong contact between the antigen and the immune system. In addition, sustained release compositions obviate the need for discrete multi-dose administration of the antigen and permit the required amount of antigen to be delivered to GALT in one or two daily doses. This substantially improves patient compliance.

Parenteral Administration of Antigen -  
An Alternative to Multi-Dose Oral Administration

An alternative method within the scope of the present invention for accomplishing tolerance of Th2 responses is a method comprising prolonged parenteral infusion of a subject to be treated with an autoantigen. For humans, the duration of each treatment will be, for example, from about 1 hour to about 24 hours of continuous infusion repeated at intervals of 1-4 weeks as needed. Upward or downward adjustments to the infusion time can be made based on the patient's response. A preferred route of parenteral administration is intravenous administration. Suitable parenterally deliverable amounts of antigen are within the range of about 2.5 to about 250 mg of antigen. Suitable formulations include sterile solutions of antigen suitable for parenteral administration in an appropriate medium (e.g., saline in distilled water etc.). Buffers, emulsifiers, salts and other optional ingredients suitable for such preparations can be included. Purified antigen should be administered without co-stimulatory factors (which would induce an immune response against the antigen). Suppression is accomplished by anergy or clonal deletion.

The invention is further described below by reference to examples, the purpose of which is to illustrate the present invention without limiting its scope.

All documents cited herein are incorporated by reference therein. In case of conflict, however, the present specification including its definitions will control.

Examples 1 - 5

30 Experimental Animals

Female BALB/C mice, 6-8 weeks of age, were used in all experiments. The mice were bred at the department of Animal Sciences, Hebrew University of Jerusalem, Rehovot, Israel, where they are periodically crossed with wild-type Balb/c mice. The animals were maintained in a temperature and light-controlled environment with free access to feed and water. During experiments mice fed with OVA intermittently several times during the day (see below) had free access to OVA

solution in water, instead of water alone. Each experimental group contained no less than 5 mice.

#### Antigens, Feedings and Immunizations

5           Antigens used were ovalbumin (OVA) (from Sigma Chemicals Co., St. Louis, MO) and purified protein derivative PPD (Statens, Denmark). Oral tolerance to OVA was induced by multi-dose oral exposure to a sterile solution of OVA in drinking water (1 mg/mL, unless otherwise stated) for a period  
10 of 20 days (unless otherwise stated). Each mouse consumed  $4 \pm 0.25$  mL solution/day. In several experiments, mice were fed 20 intermittent boluses of OVA in water (4 mg OVA/feeding) over the period of 20 days. Mice were immunized against OVA by injecting 20  $\mu$ g OVA/mouse, either emulsified 1:1 in CFA, or  
15 absorbed by 1 mg  $\text{Al}(\text{OH})_3$ . Injections (100  $\mu$ l/mouse) were administered IP (for spleen and mesenteric lymph node [LN] analysis) or subcutaneously in hind foot-pads (for popliteal LN analysis).

#### 20 Assay for anti-OVA antibodies

          Presence of IgG1, IgG2a and IgG2b serum antibodies specific for OVA was tested by ELISA as described (4, 18). Serial two-fold dilutions of anti-OVA antisera were placed on ELISA plates (Nunc, Denmark), previously coated with OVA,  
25 followed by biotinylated rat anti-mouse IgG1, IgG2a or IgG2b monoclonal antibodies (Pharmingen, San Diego, CA), and finally by peroxidase-streptavidin (Kirkegaard & Perry Laboratories [KPL], Gaithersburg, MD). Bound antibodies were detected by ABTS (KPL). Due to low serum concentrations of IgE, an OVA-  
30 specific IgE ELISA protocol was developed. Plates were coated with 2  $\mu$ g/mL monoclonal anti-mouse IgE (Southern Biotechnology Associates, Birmingham, AL). After blocking, serial two-fold serum dilutions were added, followed by OVA (50  $\mu$ g/mL in PBS), then by mouse anti-OVA hyper-immune serum (1:1000), and finally  
35 by peroxidase-goat anti-mouse IgG ( $\gamma$  chain specific) (KPL). Bound antibodies were detected by the addition of ABTS. Antibody titers are averages of no less than 5 individual mice and are expressed in absorbance units at 405 nm  $\pm$  SEM.



### Cell cultures

Spleen (erythrocyte depleted) and lymph node (LN) cell (popliteal and mesenteric) cultures were used for proliferation, cytokine secretion and cytokine gene expression assays. Cultures contained pooled cells from no less than 5 mice. The proliferation of T lymphocytes in spleen and LN cell cultures was assayed as described (14,19). Proliferation was measured by MTT oxidation (14,19), and results are averages of quadruplicate cultures expressed in absorbance units (at 570-10 630 nm)  $\pm$  SEM. For cytokine secretion,  $1 \times 10^7$  cells/well (in 1 mL) were cultured in 24 well plates (Nunc, Denmark) with or without OVA 1 mg/mL. Cytokine secretion was determined temporally in supernatants collected from these cultures and was ascertained to be optimal after 9 hours culture for IL-415 detection, 20 hours for IL-2 detection, and 48 hours for IFN $\gamma$  detection. Collected supernatants were frozen and stored at -70°C till assayed (see below). For the assay of cytokine gene expression,  $5 \times 10^7$  spleen cells/ml were cultured with or without OVA (1 mg/mL) for 6 hours. Following incubation, cells20 were collected and total RNA was isolated for RT-PCR (see below). DMEM was used for all cultures, and was supplemented with 100 U/ml penicillin, 100  $\mu$ g/mL streptomycin, 2 mM L-glutamine, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids (all supplied by Biological Industries, Beit Haemek,25 Israel),  $5 \times 10^{-5}$ M 2-mercaptoethanol and 0.5% syngeneic serum.

### Cytokine assays

Levels of IL-4, IL-2 and IFN $\gamma$  in supernatants were determined by capture ELISA as described (3,4,20). Briefly,30 supernatants were added to microtiter plates, previously coated with rat anti-mouse IL-4, IL-2 or IFN $\gamma$  monoclonal antibodies (capture antibodies, Pharmingen) and blocked with BSA-diluent/blocking solution (KPL). Biotinylated rat anti-mouse IL-4, IL-2 or IFN $\gamma$  monoclonal antibodies (detecting antibodies,35 Pharmingen) were added and followed by peroxidase-labeled streptavidin. Bound cytokine was detected by the addition of ABTS (Kirkegaard & Perry). Cytokine levels were calculated from a log-log plot of absorbance vs. concentration of

recombinant cytokines (Pharmingen), and results are expressed in pg/mL (for IL-4 and IL-2) or ng/mL (for IFN $\gamma$ ). Threshold sensitivities of ELISA assays were 5 pg/mL, 10 pg/mL and 2.5 ng/mL for IL-4, IL-2 and IFN $\gamma$ , respectively. As a confirmation, IL-2 and IL-4 levels were also determined by bioassay using the CTLL-2 (IL-2 dependent) and CT.4S (IL-4 dependent; kindly provided by Dr. W.E. Paul, NIH, Bethesda, MD) cell lines as described (4).

10 Analysis of cytokine mRNA levels

Total RNA was isolated from cultured spleen cells using a TRI reagent (Molecular Research Center, Inc., Cincinnati, OH), according to a protocol provided by the manufacturer. mRNA was then reverse transcribed into cDNA, and the expression levels of IL-4, IL-2, IFN $\gamma$  and  $\beta$ -actin messages were determined by a quantitative polymerase chain reaction (PCR) using cytokine specific primers.  $\beta$ -actin, IL-2 and IFN $\gamma$  primer sequences were from Stratagene (La Jolla, CA). IL-4 sequences were as follows: IL-4 sense: 5'-CAGCTAGTTGTCATCCTGCTC-3' (76-97) and IL-4 antisense: 5'-CAGGAAGTCTTTTCAGTGATGTGAA-3' (445-421). All primers used spanned genomic introns such that any contaminating genomic DNA was detected by a higher molecular weight band. Quantitative PCR conditions were first established for all sets of primers using either cDNA from Con A activated spleen cells or plasmid DNA. These were subjected to 8 two-fold serial dilutions and amplified for 25 cycles at 95°C for 25 seconds, 60°C for 60 seconds and 72° for 60 seconds in a 9600 Geneamp PCR System (Perkin-Elmer Cetus Corp., Branchburg, NJ). [<sup>32</sup>P]dCTP was added directly into the PCR reaction as described (21), and the products were resolved on 5.5% acrylamide gel. mRNA was quantitated using a  $\beta$ -scope (Intelligentics, Mountain View, CA). Tested cDNA samples were amplified undiluted and with two additional two-fold dilutions with cytokine specific primers, and at 1/100, 1/200 and 1/400 serial dilutions with  $\beta$ -actin primer sequences. The ratio of cytokine mRNA expression relative to  $\beta$ -actin was obtained for each dilution and expressed as the mean ratio  $\pm$  SE (see all columns in Table III,

except for the columns labeled "ratio" which show the ratio of the value of the column labeled OVA over the value of the column labeled "medium" and thus compares the OVA readings against the background).

5

#### Statistical analysis

The statistical significance of differences between experimental groups was determined using unpaired two-tailed Student's t-test, with differences considered significant at

10  $P < 0.05$ .

Example 1:      Exposure of mice to multiple doses of OVA induces OVA-specific T lymphocyte unresponsiveness in vitro.

15

To determine if tolerance could be induced in both Th1 and Th2 lymphocyte subsets, we exposed (orally tolerized) mice to OVA in their drinking water (ad libitum consumption). Exposure was continued for 20 days, and then mice were  
20 immunized by OVA-CFA. Control mice were primed by OVA-CFA or CFA alone. Spleen cell cultures were prepared 10 days after immunization and T lymphocyte proliferation in response to OVA (Fig. 1A) or PPD (Fig. 1B) was determined. T lymphocytes did not proliferate in response to OVA but exhibited a dose  
25 dependent response to PPD which was similar to that of the OVA-primed, non-tolerant control group (Fig. 1A-1D ;  $P < 0.05$  for all antigen doses, representative of 6 experiments). Identical observations were made with LN (popliteal and mesenteric) cell cultures, with other protein antigens (human serum albumin  
30 [HSA], and hen egg lysozyme (HEL) and with Al(OH)<sub>3</sub> as adjuvant (data not shown). Thus, multi-dose oral exposure to external antigens in solution is not an immunogenic stimulus, but rather induces antigen-specific T lymphocyte unresponsiveness, as determined by absence of T lymphocyte proliferation.

35

In more detail, Figures 1A and 1B depict graphically the results of experiment involving multi-dose oral exposure to OVA and show that such exposure diminishes T lymphocyte proliferation response in vitro. Mice were multi-dose exposed to OVA in drinking water for 20 days and primed by OVA-CFA

(open triangles). Control mice were primed by OVA-CFA (filled circles) or CFA alone (open circles). Control mice were primed by OVA-CFA (filled circles) or CFA alone (open circles). Pooled erythrocyte-depleted spleen cells were prepared 10 days after immunization and stimulated by different concentrations of OVA (Fig. 1A) or PPD (Fig. 1B). Results are averages  $\pm$  SEM of quadruplicate cultures containing pooled cells from at least 5 mice, and are expressed in absorbance units at 750-630 nm.

The results of this experiment show that multi-dose oral administration of antigens suppresses proliferation of antigen-specific T-lymphocytes and therefore suppresses a T-cell response.

Example 2: Determination of absence of both Th1 and Th2 cytokine secretion in cultures derived from mice exposed to multiple doses of OVA in drinking water.

Absence of proliferation is only partially indicative of tolerance, since activated non-dividing cells may produce cytokines (22,23). Thus, to further establish an *in vitro* state of tolerance in T lymphocytes derived from mice exposed to multiple doses of OVA in their drinking water, *in vitro* cytokine secretion was determined. Mice, multi-dose fed OVA (1 mg/mL) in drinking water for 20 days or non-fed controls, were immunized I.P. by OVA-CFA or OVA-Al(OH)<sub>3</sub> alone; two additional non-fed groups were primed by either CFA or Al(OH)<sub>3</sub> alone. Spleen cell cultures were prepared 10 days after immunization, incubated with or without OVA, and supernatants were collected to determine secretion of IL-4, IL-2 and IFN $\gamma$  (Table 1, representative of 5 experiments).

In more detail, the results in Table 1 were generated as follows: pooled, erythrocyte-depleted, spleen cells ( $10 \times 10^6$ /mL) were cultured 10 days after immunizations with or without OVA or PPD (1 mg/mL). Cytokine secretion was determined by ELISA. Cytokine levels were calculated from a log-log plot of absorbance vs concentration of recombinant cytokines. Results are averages of quadruplicate cultures pooled from at least 5 mice  $\pm$  SEM. Values in bold lettering

indicate significant cytokine secretion above threshold levels ( $P < 0.05$ ).

Mice exposed to multiple doses of OVA did not secrete IL-4, IL-2 or IFN $\gamma$  in response to OVA (not at the designated time points and not at any other time point during a 48-hour culture period), suggesting that both Th2 (IL-4 secretors) and Th1 (IL-2 and IFN $\gamma$  secretors) OVA specific lymphocytes were tolerant. This conclusion is supported by the following observations:

1) The three cytokines were secreted in response to OVA in control cultures derived from OVA-CFA and OVA-Al(OH)<sub>3</sub> primed mice, but not in those derived from mice primed by CFA or Al(OH)<sub>3</sub> alone, thus indicating OVA-specific activation of both Th1 and Th2 lymphocytes in two adjuvant systems ( $P < 0.05$ ).

2) Tolerance was OVA-specific as evidenced by the capacity of cells from OVA-exposed mice to secrete cytokines in response to PPD ( $P < 0.05$ ).

The possible presence of IL-4 and IL-2, undetected by ELISA, was further evaluated by bioassays using CT.4S (available from the NIH) and CTLL-2 (commercially available from the ATCC) cells, respectively; IL-2 and IL-4 were not detected in cultures derived from mice exposed to multiple doses of OVA, HSA or HEL, and identical observations were obtained with LN cell cultures (data not shown). The results of these experiments establish that multi-dose oral exposure to antigen in solution induces specific tolerance of Th2 and Th1 lymphocytes as determined by *in vitro* proliferation and cytokine secretion.

Example 3: Determination that mice exposed to multi-doses of OVA in drinking water do not express Th1 and Th2 cytokine genes.

To further evaluate the level of tolerance induced by exposing mice to multiple doses of OVA, we measured cytokine gene expression in response to OVA.

Mice, multi-dose fed or non-fed controls, were immunized by OVA-CFA; an additional non-fed group was primed

by CFA alone. Spleen cell cultures were prepared 10 days after immunization, incubated with or without OVA, and cells were collected to determine IL-4, IL-2 and IFN $\gamma$  mRNA expression by quantitative PCR (Table 2, representative of 3 experiments).

5 In more detail, the results in Table 2 were generated as follows: mice were exposed to multiple doses of OVA in drinking water for 20 days (1 mg/mL OVA in water) and then immunized I.P. by OVA-CFA. Control non-fed mice were primed by OVA-CFA.

10 Pooled erythrocyte-depleted spleen cells ( $5 \times 10^7$ /ml) were cultured 10 days after immunizations with or without OVA (1 mg/mL) for 6 hours. Cells were collected and total RNA was isolated. mRNA was reverse transcribed into cDNA and the expression levels of IL-4, IL-2, IFN $\gamma$  and  $\beta$ -actin messages were  
15 determined by quantitative PCR using cytokine specific primers, as described in Materials and Methods. Visualized bands were quantitated using a  $\beta$ -scope, and cytokine mRNA expression values are relative to those of  $\beta$ -actin mRNA used as an internal control  $\pm$  SEM. In addition, mRNA expression is  
20 presented as the ratio between mRNA expressed in response to OVA and that expressed in response to medium alone. Values in bold lettering indicate significant mRNA expression above levels expressed in response to medium alone ( $P < 0.05$ ).

The data show that IL-4, IL-2 and IFN $\gamma$  mRNA were not  
25 expressed in response to OVA by cells derived from mice multi-dose fed with OVA. In contrast, IL-4, IL-2 and IFN $\gamma$  mRNAs were specifically elevated in control cultures ( $P < 0.05$ ). Hence, the state of tolerance in Th2 and Th1 lymphocyte subsets was confirmed by absence of cytokine gene expression following a  
30 specific antigen stimulus. These results confirm that oral multi-dose administration of an antigen suppresses the occurrence of antigen-specific Th2 and Th1 cells and therefore suppresses an immune response to the antigen.

Example 4:      Determination that mice exposed to multiple doses OVA do not secrete Th2 and Th1 dependent antibodies in vivo.

The previous observations indicated that multi-dose feeding of OVA induced a state of tolerance in Th2 and Th1 lymphocyte subsets, as determined by *in vitro* analysis. To confirm that a similar state was present *in vivo*, we studied profiles of antibodies produced in response to OVA stimulation in tolerant mice. Antibody isotype profiles serve as relative indicators of murine Th subset activity *in vivo*; IgG1 and IgE production is regulated by IL-4 and represents a Th2 mediated response, whereas IgG2a and IgG2b production is regulated by IFN $\gamma$  and represents a Th1 mediated response (24,25). Mice were multi-dose fed with OVA for 20 days and then primed by OVA-CFA. Control mice were primed by OVA-CFA or CFA alone. Serum samples were collected temporally after immunization (15-60 days) and analyzed for OVA-specific IgG1, IgE, IgG2a and IgG2b secretion (Figs. 2A-2D, antibody titers in serum 15 days after immunization, representative of 5 experiments).

Figure 2 depicts graphically the results of experiments in which mice were multi-dose fed with OVA for 20 days (1 mg/ml) and primed by OVA-CFA (open triangles). Control mice were primed by OVA-CFA (filled circles) or by CFA alone (open circles). Serum samples were collected 15 days after immunization and individually assayed for IgG2a (Fig. 2A), IgG2b (Fig. 2B), IgG1 (Fig. 2C) and IgE (Fig. 2D) by ELISA. Antibody titers are averages  $\pm$  SEM of titers from individual mice (for all isotypes) and are expressed in absorbance units at 405 nm. Each experimental group contained at least 5 mice.

As shown in Fig. 2, mice fed multiple doses of OVA did not produce any detectable antibody response to OVA; thus anti-OVA IgG1 and IgE, as well as IgG2a and IgG2b, levels were completely diminished. In contrast, control mice primed by OVA-CFA developed significant responses that consisted of all antibody subclasses, indicating that CFA was capable of supporting both Th2 and Th1 mediated responses *in vivo* (Al[OH]<sub>3</sub> promoted selective Th2 mediated antibody production and could not be used to confirm Th1 tolerance). Antibody production was intact in tolerant mice as evidenced by presence of all four

subclasses in response to PPD; levels were similar to those of control OVA-CFA immunized mice, and similar results were obtained 20, 30, 45 and 60 days after immunization (data not shown). Taken together, the results show that both Th2 and Th1 responses are susceptible to antigen-specific tolerance induction by multi-dose oral exposure to an amount of antigen above a threshold amount.

10 Example 5: Characterization of the tolerogenic signal required for tolerization of Th2 lymphocytes.

Since selective tolerization of Th1 lymphocytes was accomplished by means of a different feeding regimen (by a single or an intermittent feeding regimen; see e.g. ref. 4), it was of interest to determine comparative requirements for inducing Th2 lymphocyte tolerance. Three parameters were studied: 1) the rigidity of the feeding regimen, namely the necessity for multi-dose exposure compared with a less-frequent intermittent (e.g. once daily) feeding regimen; 2) the minimal antigen dosage required for effective tolerization of Th2 lymphocytes; 3) the minimal period required for effective tolerization of Th2 lymphocytes.

The importance of the feeding regimen for tolerization of Th2 lymphocytes was studied by comparing the degree of tolerance generated by multi-dose exposure to OVA in drinking water for 20 days to that generated by an intermittent (in this experiment on alternate days) feeding regimen in which mice received the same average dose of OVA ( $4 \pm 0.25$  mg/day). Mice were then immunized by OVA-CFA, and responses of both groups to OVA were compared 15 days after immunization (Table 3, representative of 4 experiments).

Table 3 was generated from data from the following experiment: mice were either exposed to multiple doses of OVA (1 mg/mL) or received daily boluses containing 4 mg/mL for 20 days.

35 Details of cytokine measurement are as in Table 1; concentrations are pg/mL for IL-2 and IL-4, and ng/mL for IFN $\gamma$ . OVA specific responses are averages of quadruplicate cultures  $\pm$  SEM, and values in bold lettering indicate significant



cytokine secretion above background threshold levels (see Table 1) ( $P < 0.05$ ).

Serum IgG2a and IgE were measured 15 days after immunization by isotype specific ELISA, and anti-OVA specific responses are expressed in absorbance units at 405 nm. The values of IgG2a and IgE are from serum dilutions of 1:100 or 1:40 respectively, and are averages of at least 5 individual mice  $\pm$  SEM. Values in boldface indicate significant secretion as compared to levels in naive serum (mean absorbance  $0.15 \pm 0.02$ ) ( $P < 0.05$ ).

Th1 and Th2 tolerance resulted from the multi-dose feeding regimen (both *in vitro* cytokine production and *in vivo* antibody secretion), whereas the intermittent feeding regimen caused selective Th1 tolerance while Th2 responses (cytokine and antibody) were unchanged, apart from a minor reduction in IL-4 secretion ( $P < 0.05$ ). Hence, the method of antigen exposure (multi-dose daily vs. intermittent) at the particular level of antigen administered was important for generation of Th2 tolerance.

The minimal antigen dosage required for effective tolerization of Th2 lymphocytes was determined by multi-dose exposure of mice to different concentrations of OVA in drinking water (0-1 mg/mL) for 20 days. OVA specific cytokine production *in vitro* and anti-OVA IgG1 and IgG2a production were assayed 15 days after immunizing mice with OVA-CFA (Fig. 3, representative of 4 experiments).

In the experiment that gave rise to Fig. 3, mice were multi-dose fed with different dosages of OVA for 20 days, and primed by OVA-CFA. Spleens and serum samples were collected 15 days after immunization to determine cytokine (circles) and antibody (triangles) secretion respectively. Erythrocyte-depleted spleen cells were cultured as detailed in the description of the experiment for Table 1, and supernatants were added to cultures of CTLL-2 or CT.4S cells for detection of IL-2 (solid circles) and IL-4 (open circles) respectively. Results are averages  $\pm$  SEM of quadruplicate cultures and are expressed in absorbance units at 570-630 nm. IgG2a (solid triangles) and IgG1 (open triangles) were determined by ELISA.

Antibody titers are averages of antibody binding  $\pm$  SEM from individual mice at a serum dilution of 1:400 and are expressed in absorbance units at 405nm. Each experimental group contained at least 5 mice.

5           Results in Fig. 3 show that tolerization of cytokine secretion *in vitro* and antibody responses *in vivo* required multi-dose exposure to 1 mg/mL OVA ( $P < 0.05$ ). A dosage of 0.01 mg/mL had no effect on T lymphocyte functions ( $P > 0.05$ ), and 0.1 mg/mL had only marginal effects on the measured  
10 functions ( $P = 0.05$ ). Hence, effective oral tolerization of both Th1 and Th2 controlled responses (cytokine and antibody production) required dosages of this antigen in excess of 0.1 mg/mL. This shows that there is a minimum effective amount of orally administered antigen.

15           The minimal period required for effective tolerization of Th2 lymphocytes was determined by evaluating the temporal degree of tolerance generated *in vivo* by exposing mice to multiple doses of OVA (1 mg/mL). Mice were immunized temporally after feeding was initiated, and serum samples were  
20 collected, in each case, 15 days after immunization, and then assayed by ELISA for IgG1 and IgG2a (Fig. 4, representative of 5 experiments).

For the experiment of Fig. 4, mice were exposed to multiple doses of OVA for different periods (1-20 days). After  
25 each exposure period mice were immunized by OVA-CFA. Individual sera were prepared 15 days later and assayed by ELISA for anti-OVA IgG1 (open circles) and IgG2a (solid circles). Results are average antibody binding  $\pm$  SEM from individual mice at a serum dilution of 1:400, and are presented  
30 in absorbance units at 405nm. Each experimental group contained at least 5 mice. Similar binding patterns were seen at serum dilutions ranging from 1:10 up to 1:800; antibody activity attained background values (0.155) at a dilution of 1:1600.

35           As shown in Fig. 4, Th1 mediated responses were most sensitive to tolerance induction: a single-day period of multi-dose exposure to OVA was sufficient to dramatically reduce specific IgG2a production (Th1-controlled), which essentially

ceased after 5 days of exposure. In comparison, Th2 controlled responses were highly resistant to tolerance induction and became so only after 20 days of multi-dose exposure to antigen: anti-OVA IgG1 production gradually diminished with time of exposure to OVA and attained background values only after 15-20 days of exposure. To summarize, oral tolerization of Th1 lymphocytes was achieved after a brief and intermittent exposure period to antigen. On the other hand, oral tolerization of Th2 lymphocytes was achieved only after extended periods of exposure to antigen and, at this amount per feeding, antigen needed to be administered in a multi-dose daily schedule. This shows that there is a minimum effective period of exposure to antigen, which is longer for Th2 than for Th1 suppression.

The results of this experiment show that there is a minimum effective amount of an antigen for inducing tolerance of a Th2 response specific to that antigen. The results also show that there is an interrelationship between the antigen amount fed and the frequency of the administration on one hand, and the effectiveness of the suppression on the other. More frequent (multi-dose daily) administration increases the effectiveness of tolerization. Moreover, oral tolerization of Th2 responses requires a longer period of treatment than oral tolerization of Th1 responses.

25

Example 6: Frequency of CD4+, V $\beta$ 8.2+ T cells in Peyer's patch following antigen feeding.

Ovalbumin (OVA) specific TcR-transgenic mice (n=6-9/group) that express the V $\alpha$ 13/V $\beta$ 8.2 TcR on 97% of peripheral T cells (Murphy et al., *Science* 250, 1720-23 (1990)) were fed every other day for a total of up to five feedings with 0.5, 5, or 500 mg OVA. Members from each group were sacrificed either prior to the initiation of feeding or 24 hr after each feeding to provide data for no feeding or for intermediate feeding frequencies. Peyer's patches (5-8 per mouse) were harvested from the small intestine and a single cell suspension was prepared as described in Santos et al. *Cell. Immunol.* 157, 439-447 (1994). Cells were first centrifuged through a ficoll-

isopaque gradient and then stained for CD4 (with PE-conjugated YTS 191.1 mAb, Caltag, San Francisco, CA) and V $\beta$ 8.2 (with FITC-conjugated MR5-2 mAb, Pharmingen, San Diego, CA). Fluorescence was analyzed on a Becton-Dickinson FACSsort using Lysis II software. Data collection was gated on live cells through propidium iodide exclusion and data represent 10,000 events presented as probability (15%) contours. The percentage of V $\beta$ 8.2+ T-cells which are CD4+ as seen with each additional feeding is graphed in Figure 5A. Each data point in the Figure represents an average from 6-10 mice pooled from three independent experiments. The statistical significance (chi square analysis) of frequency differences of CD4+, V $\beta$ 8.2+ T cells among the various groups was as follows: for 0.5 mg fed,  $p < 0.001$  versus 5 mg, 500 mg and unfed after 3 and 5 feedings; for 5 mg and 500 mg fed,  $p < 0.001$  versus unfed after 3 and 5 feedings.

Exposure to small doses of OVA steadily increases the percentage of V $\beta$ 8.2+ cells that are CD4+ in the Peyer's patches, while larger doses -- 5 mg, 50 mg (not shown but similar to 5 mg) and 500 mg -- decrease the number which are CD4+. As seen in Figure 5A, in animals fed 500 mg, by the third feeding the percentage of CD4+, V $\beta$ 8.2+ T cells has decreased from 20% (unfed) to less than 1.5%. The decrease was not the result of an increase in the non-T cell population, as feeding was also associated with a 10-25% decrease in the total number of Peyer's patch cells. No effect was observed when OVA-TcR transgenic animals were fed 500 mg of bovine serum albumin and feeding 500 mg OVA did not affect the T cell frequency in Peyer's patches of non-transgenic animals (data not shown).

With the 500 mg feeding, a transient increase in CD4+ cell population was seen after one feeding. This was further investigated in Example 8.

There was no infiltration by CD4+, TcRV $\beta$ 8.2+T cells of other lymphoid or nonlymphoid organs such as lung or liver (based on animals feed 500 mg OVA 3 - 5 times).

These results demonstrate that antigen-specific CD4+ T-cells are considerably suppressed following feeding of a

large amount of antigen for several times though neither multi-dose nor daily feedings are required at this level of antigen per feeding. These results complement the daily multi-dose experiments described above in showing high suppression  
5 antigen-specific T-cells with several, intermittent, frequent (though not necessarily daily) feedings of larger doses of antigen.

Figures 5B and 5C are fluorescence (FACS) contour plots of Peyer's patches from animals fed 5 times with either  
10 PBS (Fig. 5B) or OVA (Fig. 5C). These panels show the same data described above but illustrate pictorially the virtual absence of CD4+ cells from the upper right-hand quadrant of the FACS plot.

15 Example 7: Frequency of apoptosis of V $\beta$ 8.2+ T cells in Peyer's patch following antigen feeding.

To determine whether the loss of CD4+, V $\beta$ 8.2+ cells occurred by depletion, the following experiment was performed:

Peyer's patch cells as prepared in Example 6 were  
20 stained for V $\beta$ 8.2 with FITC-conjugated MR5-2 mAb and for degraded DNA with acridine orange (Sigma, St. Louis, MO). Fluorescence was analyzed as in Example 6, and data collection was gated on live V $\beta$ 8.2+ cells. Data represent 10,000 events presented as probability (15%) contours. To demonstrate  
25 apoptosis, cells were stained with acridine orange using a modified method of Hardin et al. (*J. Immunol. Meth.* 154, 99-107 (1992)). Briefly, 10<sup>6</sup> ficoll separated cells were first stained for V $\beta$ 8.2 and then incubated in 100  $\mu$ l of DMEM culture medium containing 10  $\mu$ g of acridine orange at 25°C for 15 min.  
30 Cells were then washed and examined directly without fixation. The number of V $\beta$ 8.2+ apoptotic cells versus feeding over time is graphed in Figure 6A. Each data point in Figure 6A represents an average from 6-10 mice pooled from three independent experiments. The statistical significance (chi  
35 square analysis) of the frequency differences of apoptotic V $\beta$ 8.2+ T cells was as follows: for 500 mg fed,  $p < 0.001$  after 2 feedings versus 5 mg., 0.5 mg, and unfed; for 5 mg  $p < 0.01$  versus 0.5 mg and unfed after 3 and 5 feedings.

The Figure 6A graph indicates that feeding of 500 mg of OVA sharply increases the number of apoptotic V $\beta$ 8.2+ T-cells after the second feeding, while 5 mg induces only a gradual apoptosis increase (to 8% by the 5th feeding), and 0.5 mg induces minimal apoptosis. The increase of apoptotic cells seen in animals fed 500 mg returned to background levels by the 3rd feeding. In the animals fed 5 mg, the progressive increase reached 8% by the 5th feeding, whereas there was consistently only a minimal number of cells undergoing apoptosis in animals fed 0.5 mg. Furthermore, there was no increased deletion of CD4+, V $\beta$ 8.2+ cells observed in animals fed 0.5 mg twenty times over a one-month period (data not shown).

In situ labeling of cells for degraded DNA demonstrated a large percentage (up to 10%) of cells undergoing programmed cell death in the dome area of Peyer's patches from mice fed 500 mg OVA twice. FALS plots Fig. 6B and 6C illustrate this. This was not observed in control animals (fed 1 mg HEL) and was only minimally observed in animals fed 1 mg OVA (data not shown).

These results show that feeding large amounts of antigen induces clonal deletion of antigen-specific T-cells, which increases with repeated intermittent feeding.

**Example 8: Quantification of T cell activation in Peyer's patch following antigen feeding.**

The following experiment shows that T-cell deletion after high doses of oral antigen is preceded by T-cell activation.

Peyer's patch cells as prepared in Example 6 were stained for V $\beta$ 8.2 with FITC-conjugated MR5-2 mAb and for total DNA with propidium iodide (Noguchi in *Current Protocols in Immunology*, ed. Coligan et al., Wiley & Sons, Secaucus, N.J., 1994). Stimulation is measured by determining the number of V $\beta$ 8.2+ cells with high DNA content through propidium iodide staining because such cells are actively dividing, that is, they are in the S/G2-M phase of the cell cycle. Fluorescence was analyzed as in Example 7. The number of V $\beta$ 8.2+ cells in S/G2-M phase versus feeding over time is graphically

represented in Figure 7 with each data point representing a pooled average from 6-10 mice in three separate experiments. The statistical significance (chi square analysis) of the frequency differences of S/G2-M, V $\beta$ 8.2+ T cells was as follows:  
5 for 500 mg fed,  $p < 0.001$  after 1-3 feedings versus unfed; for 0.5 and 5 mg fed,  $p < 0.01$  versus unfed at all time points.

The Fig. 7A graph shows that feeding of 500 mg of OVA induces an initial stimulation of V $\beta$ 8.2+ cells which rapidly declines, presumably due to cell death, while stimulation  
10 induced by 5 mg and 0.5 mg feedings rise more slowly and tend to plateau at 4-5 feedings. Specifically, after one feeding of 500 mg OVA the percentage of activated cells rose to 7% and returned to 0 after five feedings. An increase in the percentage of activated cells also occurred in animals fed 0.5  
15 and 5 mg and was maximal after 3 feedings although deletion was only observed in 5 mg fed animals. In addition, approximately 18% of T cells in animals fed two times with 500 mg OVA express the cell surface activation marker CD44 with low or no CD45RB, demonstrating T cell activation following oral antigen and that  
20 this activation precedes deletion (data not shown). Figs. 7B and 7C are FALS plots v. DNA content comparing unfed animals with animals fed 5 mg OVA once.

These results show that large amounts of antigen administered orally on an intermittent schedule of frequent but  
25 not necessarily daily feedings cause activation-induced apoptosis in antigen-specific T-cells. Indeed, in this and experiments 6, 7 and 9, considerable antigen-specific induced hyporesponsiveness of T-cells was observed even though the total number of OVA-specific T-cells is very high in the  
30 transgenic animal model used.

Example 9: Measurement of activation and tolerization of Th1 and Th2 cells

To determine the subtype of the T-cells being  
35 deleted, the following experiment was performed:

OVA-TcR transgenic mice were fed and sacrificed as described in Example 6. Splenocytes,  $4 \times 10^5$  cells/well, were cultured in 0.2 ml of serum-free medium containing various

concentrations of OVA. Peyer's patches were not used because they contained an inadequate number of cells for multiple cytokine assays. Culture supernatants were collected after 40 hrs (for IL-2, IL-4, IL-10, IFN- $\gamma$ ) or 72 hrs (for TCF- $\beta$ ).

5 Cytokine concentration was determined by ELISA. Quantitative ELISA for IL-2, IL-4, IL-10 and IFN- $\gamma$  was performed using paired mAbs specific for corresponding cytokines per manufacturer's recommendations (Pharmingen, San Diego, CA). Active TGF- $\beta$ 1 (without acid treatment) was determined by a

10 sandwich ELISA as described in Friedman & Weiner, *Proc. Natl. Acad. Sci. USA* 91, 6688-6692 (1994). The results are in Figs. 8A - 8E.

Data presented represent mean of cultures with 1 mg/ml of OVA minus mean of cultures with 1 mg/ml of HEL. Each

15 data point represents an average from 4-6 mice; the standard deviation is within 15% of the mean. The experiment was repeated 3 times with similar results. The statistical significance (as determined by Student's t test) for OVA fed versus unfed was as follows:  $p < 0.0001$  for IL-2 after feeding

20 500 mg OVA 2-5 times;  $p < 0.001$  for IL-4 and IL-10 after feeding 5 mg or 500 mg OVA 3 times;  $p < 0.001$  for IL-4 and IL-10 after feeding 0.5 mg OVA 5 times.  $P < 0.001$  for IFN- $\gamma$  after feeding 5 mg or 500 mg OVA 3 times;  $p < 0.0001$  for TGF- $\beta$  after feeding OVA 3-5 times at all doses.

25 As seen in Figure 8, feeding of 500 mg (and 5 mg) of OVA initially enhances both Th1 (IFN- $\gamma$ ) and Th2 (IL-4 and IL-10) cytokines in the spleen which is completely lost with continued feeding, while IL-2 secretion decreases without prior enhancement. Feeding of 0.5 mg progressively enhances IL-4 and

30 IL-10, with a minimal effect on the production of IL-2 and IFN- $\gamma$ . (These cytokine changes are consistent with the increase of CD4+, V $\beta$ 8.2+ cells following low-dose feeding in Example 6 and the decrease of these cells in Example 7 following high-dose feeding.) This indicates that a minimum dose of antigen

35 is required for suppression of a cytokine profile, and that this amount is higher for suppression of the Th2 cytokine profile.



All three feeding regimens enhanced the production of TGF- $\beta$  by OVA-specific T-cells. This indicates that antigen-specific T-cells secreting the nonspecific immunosuppressive Factor TGF- $\beta$  are resistant to deletion by this tolerization regime. However, this is beneficial to treatment of autoimmune disease because TGF- $\beta$  has the property of suppressing all immune responses in the vicinity of its release, including autoimmune responses.

#### 10 Further Experiments

Splenic T cell proliferative responses were greater than 90% suppressed in OVA fed vs. nonfed animals ( $3,432 \pm 52$  vs.  $47,079 \pm 6,131$   $\Delta$ CPM) measured by tritiated thymidine uptake and antibody responses (measured by ELISA) were suppressed by 50-75% in mice fed 500 mg OVA 5 times followed by subcutaneous immunization with 100  $\mu$ g OVA/CFA. Anti-OVA IgM titers measured by ELISA were reduced from  $512 \pm 43$  in non-fed to  $128 \pm 21$  in the fed mice; IgG1 was reduced from  $32 \pm 5$  to  $16 \pm 7$ ; and IgG2a from  $256 \pm 14$  to  $128 \pm 36$ . There were few or no detectable anti-OVA antibodies in naive transgenic mice, which indicates that all the anti-OVA antibodies were induced by immunization with OVA. In addition to deletion, evidence of anergy was also observed in mice fed 500 mg OVA. Specifically, the reduced splenic T cell proliferative responses could be partially reversed (from  $3,432 \pm 52$  to  $24,227 \pm 1468$   $\Delta$ CPM) by preculture of cells with recombinant IL-2 indicating that a number of antigen-specific T-cells became unresponsive not due to apoptosis, but due to anergy.

The foregoing experiments confirm both Th1 and Th2 suppression can be achieved using intermittent oral administration of large amounts of antigen. Thus, when treating antibody-mediated autoimmune diseases, an oral feeding regimen involving large amounts of autoantigen administered in single doses intermittently is indicated as one effective way of suppressing Th2 responses to that antigen.

Examples of Human TreatmentExample A: Myasthenia Gravis

An individual afflicted with *myasthenia gravis* is first orally administered 2.5 mg. of nicotinic acetylcholine receptor once a day for 1 week to eliminate the unlikely possibility of adverse reaction. Following this, the daily dosage is increased to 10 mg for a period of one to two weeks at the end of which the patient's antibody responses are measured using immunoassay (for reactivity to acetylcholine receptor). If no improvement is seen the daily dosage is increased (progressively) to 25, 50 or 100 mg etc. (and the antibody responses are monitored weekly or every two weeks) until an effective dosage is determined. (The number of daily doses may also be increased to six daily either instead of or in addition to an increase in total daily amount of antigen administered.) Once an effective amount and administration schedule has been identified for this patient (over the course of no more than several weeks) therapy continues at this amount and schedule for at least three months. Periodically, muscle strength is tested to monitor progress. (Muscle strength can also be used as an indicator of treatment efficacy instead of antibody responses during the phase of determining appropriate dosage and schedule.)

Example B: Autoimmune Thrombocytopenic Purpura

An individual afflicted with this disease is subjected to the same regimen as in Example A except that platelet count is monitored (weekly) and preferably glycoprotein IIb-IIIa are used as the orally administered autoantigen. A dosage is effective when increased platelet counts are normal or approach normal but do not increase further with additional orally administered antigen. Alternatively, an immunoassay measuring antibodies to platelets can be used to monitor the patient's progress.

Example C: Autoimmune Thyroiditis

An individual suffering from Hashimoto's disease is subjected to the same regimen as above but thyroglobulin is used as the antigen at the same amounts as in Example A.

Effectiveness of a particular regimen, is assessed and the patient's progress is monitored by decrease in antithyro-globulin autoreactive antibody. Preferably, the patient should receive treatment at a particular dose for at least 3 - 4 weeks before effectiveness can be assessed. If indicated, the number of daily dosages can be increased.

The same procedure can be followed for a patient suffering from Grave's disease, another type of autoimmune thyroiditis except that TSHR would be the autoantigen orally administered and therapeutic progress will be monitored, e.g., by decrease in anti-TSHR autoreactive antibody titer, or TSH levels.

The invention has been described above by reference to preferred embodiments. It will be understood that many modifications are possible within the scope of the claims that follow.

All documents, patents and patent applications are incorporated by reference in their entirety. In case of conflict, the present disclosure including its definitions controls.

Table 1.

Continuous exposure to OVA diminishes cytokine secretion in vitro.

5	OVA	Immunization	IL-4 (9 h, pg/ml)		IL-2 (20 h, pg/ml)		IFN $\gamma$ (48 h, ng/ml)	
			OVA	PPD	OVA	PPD	OVA	PPD
10	--	CFA	< 5	94 $\pm$ 7	< 10	250 $\pm$ 13	< 2.9	75 $\pm$ 4
	--	OVA-CFA	41 $\pm$ 3	87 $\pm$ 5	133 $\pm$ 7	235 $\pm$ 17	37 $\pm$ 4	87 $\pm$ 9
	Continuous	OVA-CFA	< 5	98 $\pm$ 8	< 10	262 $\pm$ 19	< 2.8	75 $\pm$ 7
	--	Al (OH) <sub>3</sub>	< 5	ND	< 10	ND	< 2.6	ND
	--	OVA-Al (OH) <sub>3</sub>	32 $\pm$ 4	ND	55 $\pm$ 2	ND	21 $\pm$ 2	ND
	Continuous	OVA-Al (OH) <sub>3</sub>	< 5	ND	<10	ND	< 2.9	ND

Table 2.

Effect of continuous exposure to OVA on cytokine mRNA expression

5	OVA	<u>IL-4 mRNA</u>			<u>IL-2 mRNA</u>			<u>IFN<math>\gamma</math> mRNA</u>		
		Medium	OVA	Ratio	Medium	OVA	Ratio	Medium	OVA	Ratio
	Fed									
	--	0.7 $\pm$ 0.1	2.1 $\pm$ 0.1	3.0	2.9 $\pm$ 1.0	5.8 $\pm$ 1.0	2.0	0.9 $\pm$ 0.2	5.9 $\pm$ 0.5	6.6
	Continuous	1.0 $\pm$ 0.0	1.0 $\pm$ 0.0	1.0	0.3 $\pm$ 0.0	0.2 $\pm$ 0.0	0.7	4.2 $\pm$ 0.6	2.4 $\pm$ 0.2	0.6

Table 3.

Effect of feeding regimen on OVA specific tolerization  
of Th1 and Th2 lymphocytes

5

OVA	Immuniza- tion	Cytokine Secretion			Antibody Secretion		
		IL-4	IL-2	IFN $\gamma$	IgE	IgG2a	
Fed							
--	CFA	< 5	< 10	3.2 $\pm$ 0.3	0.13 $\pm$ 0.04	0.15 $\pm$ 0.03	
--	OVA-CFA	35.4 $\pm$ 1.8	99.8 $\pm$ 7.4	43.5 $\pm$ 4.5	0.65 $\pm$ 0.06	0.95 $\pm$ 0.07	
10 Intermittent	OVA-CFA	24.8 $\pm$ 0.9	< 10	2.8 $\pm$ 0.3	0.60 $\pm$ 0.05	0.19 $\pm$ 0.01	44
Continuous	OVA-CFA	< 5	< 10	3.1 $\pm$ 0.2	0.18 $\pm$ 0.03	0.17 $\pm$ 0.04	

## REFERENCES

1. Friedman, A., et al. 1994. *Chem. Immunol.* 58: 259.
2. Weiner, H.L., et al. 1994. *Annu. Rev. Immunol.* 12: 809.
- 5 3. Friedman, A., et al. 1994. *Proc. Natl. Acad. Sci. USA* 91: 6688.
4. Melamed, D., et al. 1994. *Eur. J. Immunol.* In press.
5. Lobell, J.F., et al. 1993. *J. Immunol.* 150 (8,11): 114A.
6. Williams, M.E., et al. 1990. *J. Immunol.* 144: 1208.
- 10 7. Go, C., et al. 1993. *J. Immunol.* 150: 367.
8. Gilbert, K.M., et al. 1992. *Cell. Immunol.* 139: 58.
9. Burstein, H.J., et al. 1992. *J. Immunol.* 148: 3687.
10. De Wit, D., et al. 1992. *J. Exp. Med.* 175: 9.
11. Peterson, J.D., et al. 1993. *Eur. J. Immunol.* 23: 46.
- 15 12. Romball, C.G., et al. 1993. *J. Exp. Med.* 178: 1637.
13. Mowat, A.M. 1987. *Immunol. today* 8: 93.
14. Melamed, D., et al. 1993. *Cell. Immunol.* 146: 412.
15. Rocha, B., 1993. *J. Exp. Med.* 177: 1517.
16. Ramsdell, F., et al. 1992. *Science* 257: 1130.
- 20 17. Strobel, S. 1991. *Eur. J. Clin. Nutr. (Suppl. 1)* 45: 1.
18. Friedman, A. 1991. *Vaccine* 9: 122.
19. Melamed, D., et al. 1993. *Eur. J. Immunol.* 23: 935.
20. Yang, X., et al. 1993. *J. Immunol.* 150: 4354.
21. Murray, R.L., et al. 1990. *Eur. J. Immunol.* 20: 163.
- 25 22. Lancaster, S.J., et al. 1993. *Nature* 363: 156.
23. Jenkins, M.K., et al. 1993. *Curr. Opin. Immunol.* 5: 361.
24. Mosmann, T.r., et al. 1989. *Annu. Rev. Immunol.* 7: 145.
25. Stevens, T.L., et al. 1988. *Nature* 334: 255.
26. Hamaoka, T., et al. 1986. *Annu. Rev. Immunol.* 4: 167.
- 30 27. Husby, S., et al. 1994. *J. Immunol.* 152: 4663.
28. Goodnow, C.C. 1992. *Annu. Rev. Immunol.* 10: 489.
29. Netmazec, D., et al. 1991. *Immunol. Rev.* 122: 117.
30. DeFranco, A.L. 1989. *Nature* 342: 340.
31. Erikson, J., et al. 1991. *Nature* 349: 331.
- 35 32. Mowat, A.M., et al. 1982. *Immunol.* 45: 105.
33. Richman, L.K., et al. 1978. *J. Immunol.* 121: 2429.
34. Gregerson, D.s., et al. 1993. *J. Immunol.* 151: 5751.
35. Whitacre, C.C., et al. 1991. *J. Immunol.* 147: 2155.

36. Challacombe, S.J., et al. 1980. *J. Exp. Med.* 152: 1459.
37. Mattingly, J., et al. 1980. *J. Immunol.* 125: 1044.
38. Miller, A., et al. 1991. *J. Exp. Med.* 174: 791.
39. Miller, A., et al. 1992. *Proc. Natl. Acad. Sci. USA* 89:  
5 421.



## WE CLAIM:

1           1. A method for treating a mammal suffering from  
2 an antibody-mediated autoimmune disease comprising  
3 orally administering to said mammal at least one  
4 autoantigen specific for said disease at a predetermined  
5 frequency of administration; and  
6 continuing said administration at said frequency at  
7 least until at least one clinical symptom of said disease has  
8 been reduced or until at least one clinical indicator  
9 associated with said disease has attained or approached its  
10 normal value.

1           2. The method of claim 1 wherein the amount of said  
2 antigen, the frequency of said administration, and said period  
3 of time are effective to suppress a Th2 cell-mediated  
4 autoimmune response associated with said disease.

1           3. The method of claim 2 wherein said mammal is a  
2 human.

1           4. The method of claim 3 wherein said disease is  
2 selected from the group consisting of: systemic lupus  
3 erythematosus, autoimmune thyroiditis, myasthenia gravis,  
4 glomerulonephritis, autoimmune hemolytic anemia, autoimmune  
5 thrombocytopenic purpura, pemphigus vulgaris, Grave's disease,  
6 Type II-diabetes, insulin resistance, and pernicious anemia.

1           5. The method of claim 3 wherein said frequency of  
2 administration comprises administering said amount of said  
3 autoantigen at multiple doses at spaced apart intervals during  
4 a single day.

1           6. The method of claim 5 which comprises  
2 administering at least 6 doses of said autoantigen per day.

1           7. The method of claim 3 comprising continuing said  
2 administration for a period of time of at least two weeks.

1           8. The method of claim 5 wherein said amount is  
2 within the range of 5 to 1000 mg of said autoantigen per day.

1           9. The method of claim 1 comprising administering  
2 to said mammal a sustained release oral dosage form comprising  
3 said autoantigen and formulated to release said autoantigen in  
4 the gastrointestinal tract of said mammal for a period of time  
5 within the range of between about 6 and between about 12 hours.

1           10. A method for treating a mammal suffering from  
2 an antibody-mediated autoimmune disease, which comprises orally  
3 administering to said mammal an autoantigen specific for said  
4 disease and continuing said administration for a period of time  
5 sufficient to accomplish at least one of the following:

6               reduce the number of autoreactive Th2 cells in said  
7 mammal recognizing said autoantigen;

8               reduce the number of autoreactive antibodies in said  
9 mammal recognizing said autoantigen; and

10              eliminate or alleviate in said mammal at least one  
11 clinical symptom or indicator associated with said disease.

1           11. A method for suppressing an autoimmune response  
2 in a mammal in need of treatment, said mammal having at least  
3 one of autoreactive Th2 cells and autoreactive antibodies that  
4 recognize an autoantigen, the occurrence of said Th2 cells and  
5 said antibodies being associated with an antibody-mediated  
6 autoimmune disease, the method comprising orally administering  
7 to said mammal said autoantigen in an amount, at a frequency  
8 of administration, and for a period of time sufficient to  
9 accomplish at least one of the following:

10              decrease the number of said Th2 cells in said mammal;

11              decrease the number of said autoreactive antibodies  
12 in said mammal; and


13              eliminate or alleviate for said mammal at least one  
14 clinical symptom or indicator associated with said disease.

1           12. The method of claim 11, wherein said frequency  
2 comprises administering multiple doses of said autoantigen  
3 daily at spaced apart intervals within each day.

1           13. A method for treating a mammal suffering from  
2 an antibody-mediated autoimmune disease comprising  
3           parenterally administering to said mammal at least  
4 one autoantigen specific for said disease;and  
5           continuing said administration for a period of time;  
6 the amount of said antigen and said period of time being  
7 effective to suppress a Th2 cell mediated autoimmune response  
8 associated with said disease.

1/15


FIG. 1A



SUBSTITUTE SHEET (RULE 26)

2/15

FIG. 1B



SUBSTITUTE SHEET (RULE 26)

3/15

FIG. 2B





FIG. 2A



4/15

FIG. 2D






FIG. 2C



5/15

FIG. 3




SUBSTITUTE SHEET (RULE 26)




6/15

FIG. 4





7/15

FIG. 5A



SUBSTITUTE SHEET (RULE 26)


8/15



SUBSTITUTE SHEET (RULE 26)

9/15

FIG. 6A



10/15




FIG. 6B





FIG. 6C

11/15

FIG. 7A



12/15

FIG. 7B





FIG. 7C



13/15

FIG. 8A





FIG. 8B



SUBSTITUTE SHEET (RULE 26)



14/15

FIG. 8C






FIG. 8D



SUBSTITUTE SHEET (RULE 26)

15/15

FIG. 8E



## INTERNATIONAL SEARCH REPORT

national application No.

PCT/US96/10386

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 39/00, 39/38, 38/28; C07K 1/00, 14/00, 17/00

US CL : 424/184.1, 185.1; 514/3; 530/350, 868

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/184.1, 185.1; 514/3; 530/350, 868

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

MEDLINE, WPIDS, APS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	ZHANG et al. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc. Natl. Acad. Sci. USA. November 1991, Vol. 88, pages 10252-10256, see entire document.	1-3, 10, 11 ----- 4-9, 12
X	GARSIDE et al. T helper 2 cells are subject to high dose oral tolerance and are not essential for its induction. Journal Immunology. 01 June 1995, Vol. 154, pages 5649-5655, see entire document.	1-3, 10, 11
Y	WEINER et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science. 26 February 1993, Vol. 259, pages 1321-1324, see entire document.	4-9, 12

☒ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be part of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means		
*P* document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

26 AUGUST 1996

Date of mailing of the international search report

17 SEP 1996

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

EVELYN RABIN

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)\*

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/10386

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 91/01333 A1 (AUTOIMMUNE, INC.) 07 February 1991 (07/02/91), see entire document.	4-9, 12
X	WO 93/15750 A1 (HAYNES) 19 August 1993 (19/08/93), see entire document.	13